The Food and Drug Administration Friday reissued its emergency use authorization for the LabCorp COVID-19 RT-PCR Test to include authorized use for asymptomatic individuals and for pooled sample testing with up to five individual specimens. FDA previously authorized emergency use of the test for patients with suspected COVID-19 and individual specimens.

“FDA’s authorization of the first diagnostic test to be used for anyone, regardless of whether they are showing symptoms of COVID-19 or have other exposure risk factors, is a step toward the type of broad screening that may help enable the reopening of schools and workplaces,” said FDA Commissioner Stephen Hahn, M.D. “By authorizing another test for use with pooled samples, we also further help increase the possibility that patients may be able to receive results sooner, while also conserving vital testing supplies, which are under increased demand during the pandemic.”

Related News Articles

Headline
Health care providers who received approval to submit a late report on how they used Provider Relief Fund payments received from July 1 to Dec. 31, 2020, must…
Headline
Hospitals are contending with an exhausted workforce, backlogs of care deferred by the pandemic, cracks in the supply chain and a tsunami of financial…
Headline
In a study examining electronic health records for adults who visited an inpatient or outpatient facility between March 2020 and November 2021, COVID-19…
Headline
The Centers for Disease Control and Prevention today released updated guidance for clinicians treating COVID-19 in patients who received the Pfizer COVID-19…
Headline
Pfizer’s COVID-19 vaccine booster for children under age 5 was 80.3% effective and well tolerated in a clinical trial involving 1,678 children who received the…
Headline
The Centers for Disease Control and Prevention yesterday recommended children age 5-11 receive a booster dose five months after completing the Pfizer COVID-19…